高出血风险患者复杂PCI术后抗血小板治疗时程:MASTER DAPT试验亚分析
MASTER DAPT试验亚分析比较高出血风险患者接受复杂或非复杂PCI后1个月与≥3个月双联抗血小板治疗(DAPT)的效果。在复杂PCI患者中, abbreviated DAPT与标准DAPT的NACE和MACCE无差异,而BARC 2、3或5出血更低;复杂PCI和/或ACS患者中结果一致。结论提示1个月后无缺血事件的高出血风险患者缩短DAPT不增加缺血事件且减少出血,与PCI复杂度无关。
要点
- 高出血风险患者复杂PCI术后1个月停用DAPT,NACE和MACCE与标准DAPT相似。
- abbreviated DAPT在复杂和非复杂PCI患者中均降低BARC 2、3或5出血。
- 复杂PCI和/或ACS患者中缩短DAPT的缺血与出血结果一致。
核心结论
- 在高出血风险且1个月时无再发缺血事件的患者中,停用DAPT与标准DAPT相比NACE和MACCE相似且出血率更低,与PCI或患者复杂度无关。
研究设计与样本
- MASTER DAPT试验亚分析,共纳入3383例非复杂PCI患者(abbreviated DAPT n=1707,标准DAPT n=1676)和1196例复杂PCI患者(abbreviated DAPT n=588,标准DAPT n=608)。
主要发现
- 复杂PCI患者中,abbreviated DAPT与标准DAPT的NACE风险比为1.03(95%CI 0.69-1.52),MACCE风险比为1.24(95%CI 0.79-1.92)。
- 非复杂PCI患者中,abbreviated DAPT与标准DAPT的NACE风险比为0.90(95%CI 0.71-1.15),MACCE风险比为0.91(95%CI 0.69-1.21)。
- BARC 2、3或5出血在复杂PCI患者中abbreviated DAPT的风险比为0.64(95%CI 0.42-0.98),非复杂PCI患者为0.70(95%CI 0.55-0.89)。
- NACE和MACCE的交互P值分别为0.60和0.26,BARC 2、3或5出血的交互P值为0.72。
- 在2816例复杂PCI和/或ACS患者中,abbreviated DAPT的NACE和MACCE无差异,BARC 2、3或5出血更低。
临床怎么用
- 对于高出血风险患者,若复杂PCI术后1个月无再发缺血事件,可考虑缩短DAPT至1个月以降低出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). METHODS AND RESULTS: In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69-1.52, and HR: 1.24, 95% CI: 0.79-1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71-1.15, and HR: 0.91, 95% CI: 0.69-1.21; Pinteraction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55-0.89; Pinteraction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. CONCLUSION: In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity. CLINICAL TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.
引用
- Valgimigli, Smits, Frigoli, et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022. PMID: 35580836. doi:10.1093/eurheartj/ehac284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。